14 Hospital Physician Board Review Manual www.turner-white.com
trial. Lancet Oncol 2010;11:1029–35.
71. Erba HP. Molecular monitoring to improve outcomes in
patients with chronic myeloid leukemia in chronic phase:
importance of achieving treatment-free remission. Am J
72. Francois-Xavier Mahon AH, Baccarani M, Mauro MJ,
et al. Treatment-free remission (TFR) in patients with
chronic myeloid leukemia in chronic phase (CML-CP) with
sustained deep molecular response on Nilotinib: ENEST-freedom, ENEStop, ENESTgoal, AND ENESTpath. J Clin
Oncol 2014 32:5s (suppl; abstr TPS7124).
73. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer
74. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL
kinase domain mutations confer polyclonal resistance to
the tyrosine kinase inhibitor imatinib (STI571) in chronic
phase and blast crisis chronic myeloid leukemia. Cancer
Cell 2002; 2:117–25.
75. Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial
of hyper CVAD and dasatinib in patients with relapsed
Philadelphia chromosome positive acute lymphoblastic
leukemia or blast phase chronic myeloid leukemia. Am J
76. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss
of major molecular response as a trigger for restarting
tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped
imatinib after durable undetectable disease. J Clin Oncol
77. Wylie MA, Schoepfer J, Berellini G, et al. Paper: ABL001,
a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic
Myeloid Leukemia. Presented at 56th ASH Annual Meeting. San Francisco, CA. December 6–9, 2014. https://ash.
confex.com/ash/2014/webprogram/Paper76344.html. Accessed May 19, 2015.
78. Goussetis DJ, Gounaris E, Wu EJ, et al. Autophagic
degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood